ALMS vs BMY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALMS and BMY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALMS and BMY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company developing oral, precision-designed therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (formerly ESK-001), is an allosteric TYK2 inhibitor that posted positive Phase 3 ONWARD1 and ONWARD2 topline results in moderate-to-severe plaque psoriasis (roughly 65% PASI 90 and over 40% PASI 100 at week 24), with an NDA submission planned for the second half of 2026. The pipeline also includes envudeucitinib in a Phase 2b lupus (SLE) trial, A-005 (a CNS-penetrant TYK2 inhibitor aimed at multiple sclerosis), and lonigutamab (an anti-IGF-1R antibody for thyroid eye disease) that came in through the 2025 merger with ACELYRIN.

Full ALMS guide

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALMS drivers: Envudeucitinib psoriasis approval path; Pipeline expansion beyond psoriasis.
• BMY drivers: New product portfolio ramp; Oncology and immunology depth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. For BMY, the central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALMS if you believe its drivers more; BMY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALMS and BMY guides.

ALMS. Alumis cannot be valued on earnings because it has no meaningful revenue and operates at a loss, so the market prices it on the probability-weighted value of its pipeline, chiefly envudeucitinib. The reported market cap reflects investor expectations for approval and launch rather than current cash flow. Balance-sheet strength from the merger and the 2026 raise matters here because runway determines how many catalysts the company can reach before needing more capital.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

Headline figures (approximate, JULY 2026): ALMS shows product revenue (ttm) ~$0 (clinical-stage, no approved products), market cap ~$2.9B, pro forma cash (post-merger) ~$737M as of Dec 31, 2024, january 2026 equity raise ~$345M gross ($17.00/share); BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%.

ALMS and BMY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALMS and BMY exposure against your real portfolio. It is not an investment adviser.